A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

ClinicalTrials.gov ID: NCT05765812

Public ClinicalTrials.gov record NCT05765812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Study identification

NCT ID: NCT05765812
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Debiopharm International SA; Industry
Enrollment: 116 participants

Conditions and interventions

Conditions

Interventions

Debio 0123 Drug
Radiotherapy Radiation
Temozolomide Drug

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 14, 2023
Primary completion: Aug 31, 2028
Completion: Aug 31, 2028
Last update posted: Apr 27, 2026

2023 – 2028

United States locations

U.S. sites: 8
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Northwestern Memorial Hospital	Chicago	Illinois	60611	Recruiting
New York University Langone Medical Center	New York	New York	10016	Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York	New York	10021	Recruiting
Baylor Scott & White Research Institute	Dallas	Texas	75246	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
South Texas Accelerated Research Therapeutics (START)	San Antonio	Texas	78229	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05765812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05765812 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →